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Summary Glutathione S-transferase sub-types a, 1t and were assessed by immunocytochemistry in 109
biopsies of ovarian tissue, comprising malignant epithelial tissue in 86 cases and tissue of ovarian origin
considered to be normal in 23. Glutathione S-transferase n was the most prevalent, being present in all except
one malignant epithelium studied and 83% of non-malignant tissue. There were no significant differences in
the overall distribution of positive staining for a, and in the malignant and non-malignant biopsies,
although the intensity of staining was greater in the malignant epithelium. Stromal staining was in general
more pronounced in the malignant biopsies, and this was particularly prominent in the case of the a sub-type.
Positive staining was seen more frequently in the less well-differentiated tumours, and a diffuse cytoplasmic
pattern was the most common observation in tumours of moderate and poor differentiation. There was no
significant association between survival and the presence or absence of sub-type staining of a and sub-type.
For the sub-type at, patient survival was found to correlate with the intensity of staining (on a 0- + + +
scale). Those patients showing resistance to cytotoxic chemotherapy were found to have a higher intensity of
staining for GSTi than responding patients.
Immunocytochemistry has made a great contribution to the
improved classification of human tumours, both in terms of
histogenesis and more recently in the related area of predic-
tion of outcome. In breast and ovarian cancers localisation
of the epidermal growth factor (EGF) receptor status and
HER-2/neu oncogene product have been shown to correlate
well with survival (Sainsbury, 1987; Slamon, 1987; Haldane
et al., 1990). These factors are primarily thought to reflect
differences in proliferation rates of the tumours, and are not
directly related to the mechanism of action of any specific
agent used in their treatment. Advances in treatment of these
tumours have been impaired by the inability to predict with
any degree of certainty which cases will respond to specific
anticancer agents, or those which show a molecular pheno-
type which makes it likely they will be insensitive to a
particular class of compounds.
There is increasing evidence that a group of proteins
associated with intrinsic or acquired resistance may be related
to response to anticancer chemotherapy. Of these, the p170
glycoprotein has now emerged as an independent predictive
factor in tumours (Chan, 1990), as well as being present in
some normal tissues including liver, adrenal, kidney and
colon (Fojo, 1987), suggesting that it may also be a marker
of intrinsic resistance.
However, resistance in human tumours is undoubtedly
multifactorial, and several other mechanisms, including alter-
ations in glutathione associated enzymes and DNA repair
mechanisms may co-exist.
It has been shown that preneoplastic hepatocytes are more
resistant than normal surrounding hepatocytes to chemical
necrosis on account of their lower capacity to activate
xenobiotics on the one hand, and their higher detoxifying
capacity on the other (Farber & Sarma, 1987). The precise
way in which the relative differences in phenotype between
normal and neoplastic cells is related to the genetic instability
of the malignant clones is as yet not clear.
The glutathione S-transferases are a family of proteins,
comprising three main classes a, 1t and x, which are known
to have several major functions among which are the
detoxification of xenobiotics (Pickett, 1989). They may play
an important role in the initial defence of the body against
potential carcinogens in sites such as the gastrointestinal tract
and liver by acting either as intercellular binding proteins or
by conjugation with glutathione (Sato, 1988). Dulik et al.
(1986) have shown that melphalan may be inactivated by the
latter mechanism. They are ubiquitous throughout the tissues
of the body, but there is considerable variation in sub-type
distribution between organs (Harrison, 1990). The n class
glutathione S-transferases are the most prevalent in human
tumours, and transfection experiments in yeast have demon-
strated they confer resistance to doxorubicin and chloram-
bucil (Black et al., 1990). There is also evidence that a class
glutathione S-transferase has a particular role in the cellular
resistance to the alkylating agents melphalan and chloram-
bucil (Lewis et al., 1988; Tew et al., 1990), while nitrosourea
detoxification may be carried out by the 1t class enzymes
(Smith et al., 1989).
There is, however, a lack of clinical studies on which to
validate these in vitro data, which have largely been derived
from cell line studies. Ovarian cancer biopsies were chosen
for this study in view of the proven role of alkylating agents
in the treatment of this disease. It was postulated that those
patients whose biopsies contained a higher content of trans-
ferases important in resistance to cytotoxic therapy may
therefore have responded less well, or relapsed at an earlier
date than those in whom expression was less pronounced.
Patients and methods
Immunocytochemistry
Neutral buffered formalin-fixed, paraffin wax-embedded tis-
sue was obtained from the files of Arrowe Park Hospital,
The Royal Liverpool Hospital, The Women's Hospital,
Broadgreen Hospital and Fazakerley Hospital. One hundred
and nine cases were investigated of which 86 were malignant.
A total of 23 non-malignant specimens were studied, com-
prising five cystadenomas, five serous cysts, three luteal cysts,
two follicular cysts, three dermoid cysts, one epithelial cyst,
two fibromas, one case of endometriosis and two cases of
normal ovarian tissue.
All of the specimens were stained for GST a, p and by
immunohistochemical staining. The methods used are as des-
cribed by Hsu et al. (1988).
Five tLm paraffin wax sections were cut from the tissue
blocks and mounted on glass slides. The sections were dried
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overnight at 37°C. They were then dewaxed and incubated in
methanol containing 3% hydrogen peroxide for 20 min. After
washing with water the sections were immersed in TRIS
buffered saline pH 7.6 containing 0.1% bovine albumin
(Sigma). They were then incubated with the primary anti-
GST antibody kindly supplied by Dr John Hayes, Depart-
ment of Clinical Chemistry, Teviot Place, Edinburgh. The
dilutions of the antibodies used were 1:800 for a and n but
1:400 for ,l. After 30 min incubation at 20°C the sections
were washed three times in TBS then Biotinylated Swine
Anti-Rabbit secondary antibody (Dako) at a dilution of
1:300 was applied. The sections were then incubated for
30 min at 20°C. Following this the sections were washed
three times in TBS then incubated in Avidin Biotinylated
Horseradish Peroxidase (Dako). After 30 min the sections
were washed three times in TBS and the peroxidase reaction
developed using diaminobenzidine solution at a concentra-
tion of 0.05% to which 0.3% of hydrogen peroxide had been
added. After 5 min the sections were washed in water then
counterstained with haematoxylin and mounted in DPX.
Negative controls were carried out using normal swine serum
at 1:400 dilution and also TBS in place of the primary
antibodies, on parallel sections. Tissue from post mortem
kidney was used as a positive control.
The intensity of staining was graded as follows, by com-
parison with the positive and negative controls: (-) negative,
(+) weakly positive, (+ +) strongly positive and equivalent
to the positive control, (+ + +) very strongly positive. Note
was also taken of whether the staining was in the cytoplasm,
the stroma or both. The staining was cytoplasmic in the
majority of cases, although in a few cases dense staining of
the nucleus was also noted. These samples had been pro-
cessed in formalin as routine surgical specimens and therefore
subject to variation in time to optimum fixation. The nuclear
staining was always accompanied by diffuse cytoplasmic
staining, and was considered likely to be due to diffusion.
Each section was accompanied by a corresponding haem-
atoxylin and eosin section for identification and categorisa-
tion of differentiation into well, moderately and poorly
differentiated.
For each case, a minimum of two paraffin blocks was
selected, examined and scored as above by one histo-
pathologist. Where a difference of more than one + was
recorded between the sections, a third block of representative
tissue was selected based on the haematoxylin and eosin
stained section. A table was constructed to allow comparison
of the intensity and distribution of staining in the malignant
and non-malignant sections. Variation in assigned staining
intensity between replicates was minimised by comparison
with the positive control for that day.
Clinical studies
The majority of the malignant cases (n = 73) were treated on
protocols comprising either oral chlorambucil (n = 6), single
agent cisplatin (n = 4) or a combination of cisplatin 80 mg
m 2 and cyclophosphamide 800 mgm-2 (n = 63) for up to
six cycles. The cases of non-malignant ovarian tissue were
obtained either from tissue adjacent to the malignant biopsies
or by searching the files of Arrowe Park Hospital Pathology
Department.
Survival was calculated by the method of Kaplan-Meier,
and differences between the curves analysed by the log-rank
method (Peto, 1977).
Results
The distribution of positive staining fcr each sub-type is
shown in Table I for the 86 malignant biopsies, and Table II
for the 23 non-malignant biopsies. GSTi was present in all
but one of the malignant biopsies in the epithelium, and
staining was more intense than with a and ti which were
present in 59% and 71% respectively of these biopsies. Illus-
trations of the positive epithelial staining in the malignant
cases are represented in Figure 1. This epithelial staining was
not found to be related to differentiation. In the stroma,
staining was of much lower intensity than seen in the
epithelium, except in the case of GSTa where strong cyto-
plasmic staining was noticed in discrete cells in the stroma
(illustrated in Figure la and b). The identity of these cells has
not been determined, but special stains have confirmed they
are neither macrophages, plasma cells or endothelial cells. In
the benign ovarian lesions the staining intensity appeared to
be of overall lower intensity, although the differences between
the malignant lesions were not significant, and the dense
positive stromal cells stained with GSTa in the malignant
biopsies were not seen. The numbers of the individual non-
malignant lesions were small, with only two with absence of
any pathology, but there were no discernable differences.
When the patients were categorised by the clinical prog-
nostic factors, age, FIGO stage (Stage I n = 18; Stage II
n = 11; Stage III n = 38; Stage IV n = 15), bulk at presenta-
tion and immediately before chemotherapy administration
(residual disease <2cm n=8; 2-5cm n= 16; >5cm
n = 13) there was no correlation shown with glutathione
transferase sub-type expression. Survival data was available
on 78 malignant patients and shown to be correlated with
stage and residual disease as expected. However, the intensity
of epithelial staining for GSTit shows a clear correlation with
outcome (Figure 2). There were 16 well differentiated
tumours, 30 of moderate differentiation and 30 of poor
histological grade. The survival curves do show a trend
towards poorer survival with loss of differentiation (data not
shown, P = 0.07), but analysis of the curves of GSTi inten-
sity by differentiation provide no evidence of an association
(+, P= 0.13; + +, P= 0.826; + + +, P= 0.867: all values
for trend). Similar trends were noted for intensity GSTa and
A against survival, but these did not reach statistical
significance.
Table I Glutathione S-transferase (GST) in 86 malignant ovarian tumours (percentages in parentheses)
GST Epithelial staining intensity Stromal staining intensity
sub- Positive Positive
type + + + + + + Total Negative + + + + + + Total Negative
ac I1(1) 12(14) 38(44) 51(59) 35(41) 4(5) 24(28) 40(47) 68(79) 18(20)
1(1) 9(10) 57(60) 61(71) 25(29) 0(0) 3(3) 23(27) 26(30) 60(70)
it 7(8) 45(53) 33(38) 85(99) 1(1) 0(0) 9(10) 44(52) 53(62) 33(38)
Table II Glutathione S-transferase classes in 23 benign ovarian lesions
GST Epithelial staining intensity Stromal staining intensity
sub- Positive Positive
type + + + + + + Total Negative + + + + + + Total Negative
at 0(0) 6(26) 10(44) 16(70) 7(30) 0(0) 6(26) 9(39) 15(65) 8(35)
A1 0(0) 5(22) 13(56) 18(78) 5(22) 0(0) 0(0) 8(35) 8(35) 15(65) it 1(4) 6(26) 12(53) 19(83) 4(17) 0(0) 0(0) 10(43) 10(43) 13(57)GLUTATHIONE S-TRANSFERASE IN OVARIAN TUMOURS 237
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Figure 1 Immunoperoxidase localisation of glutathione s-transferase distribution in malignant ovarian tumours. a GSTa x 90; b









Figure 2 Survival curve for 78 cases of ovarian carcinoma by
intensity of GSTn epithelial staining. + 27 patients; + + 44
patients; + + + 6 patients; negative one patient. x2 for trend
P = 0.0064; overall x2 p <0.0001; + vs + ++ x2 p = 0.0005; +
vs ++ X2 P=0.60.
Response to anticancer chemotherapy was available in 77
cases. A complete remission was recorded in 43 cases and a
partial remission in 12 (overall response rate 71.4% with
eight patients not evaluable). The data in Table III suggest
that resistance to anticancer therapy, assessed by progressive
disease on treatment, is associated with a high intensity of
staining for GSTi. Of the 12 patients with progressive
disease, 11 had + + or + + + staining including four show-
ing + + + intensity, while 31 out of 55 (56.4%) of the
responding patients were in these categories, with only two of
these showing + + + intensity. The Kruskall-Wallis test app-
lied to the data of tumour response against staining intensity
for GSTI gives a P value of 0.003, providing strong evidence
that staining intensity is not the same in the response
categories. Of the ten patients receiving single agent therapy,
seven were responders, and only one of the three patients
with progressive disease was in the GSTit + + + category.
As expected, the patients achieving CR performed better
than those achieving PR or SD (60% survival at 1200 days
for the patients in CR vs a median of 460 days for PR or
SD), while the median survival of the patients with progres-
sive disease was only 200 days.
Discussion
This immunocytochemical study has demonstrated the
relative predominance of GSTi in both distribution and
intensity in malignant ovarian epithelial tissue, compared to
GSTa and ft. Staining of the stroma in general mirrored that
of the epithelium, but was of much lower intensity. The
exception to this was the stromal staining for a, where foci of
+ + and + + + staining cells were noted. The identity of
these cells is not clear at present, and they did not seem to
have prognostic significance.
There was no obvious difference in the staining between
the non-malignant and malignant epithelium, or between the
stroma and staining in these categories. The non-malignant
cases comprised a heterogeneous group of conditions with a
relative predominance of dense fibrous stroma compared to
epithelium and a variable proportion of necrotic tissue, and it
is possible that some of the observed stromal staining, which
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Table III GSTi and responses to therapy - all patients receiving cytotoxic drugs
CRn=41 PR, SDn=14 PDn=12
Epithelium Epithelium Epithelium
+ + + + + + Negative + + + + + + Negative + + + + + + Negative
a - 5 18 18 - 2 3 9 - 1 8 3
A - 2 26 13 - 2 6 6 1 1 7 3
n 1 25 15 - 1 4 9 - 4 7 1 -
CR, Complete response; PR, Partial response; SD, Static disease; PD, Progressive disease.
was seldom very intense, could be artefactual. The dense
GSTa positive stromal cells were not observed in the non-
malignant cases.
The principal observations made in this series were firstly
the clear relationship between GSTn intensity and survival,
prognosis being poorer with greater intensity of GSTi stain-
ing. The effect appeared to be independent of differentiation,
and was not related to other clinical risk factors. Secondly, a
high proportion of anticancer drug resistant patients showed
intense GSTi staining. Taken together these observations
provide evidence that GSTn expression has prognostic
significance in human tumours, and lend further support for
the role of GSTic in drug resistance. However, these studies
need to be reinforced by those using alternative methods of
analysis (e.g. Western blotting) to quantify the isoenzymes.
The relationship between response to drug treatment and
survival is a complex one, as both may be sensitive to a
number of variables. The effect of proliferation rate, or
differentiation may be paradoxical in that less well
differentiated tumours may respond better to anticancer
therapy, but may also have a poor prognosis, as is well
recognised in non-Hodgkin's lymphomas, and in certain solid
tumours including ovarian cancer. A complete response in
general is the most predictive of prolonged survival but the
numbers in the individual subgroups of response and GSTIt
staining intensity are small in this study. Both are continuous
variables and have been amalgamated into groups for
analysis. In the malignant biopsies the strongest weight has
been given to the + + and + + + categories, which are
defined with reference to the positive control tissue, as nor-
mal tissues contain significant quantities of glutathione S-
transferases.
Previous studies of GST enzyme expression have only
rarely found a correlation with clinical outcome, but Holmes
et al. (1990) showed that GST7 expression was related to
outcome in leukaemia. In a recent study van der Zee et al.
(1992) found no correlation between the level of GSTc and
response to cisplatin/cyclophosphamide chemotherapy. These
authors found a reduction in GSTic biopsies taken after
chemotherapy compared to pre-treatment levels, whereas
Murphy et al. (1992) found no differences in GST activity
between 33 pre-chemotherapy and 20 post-chemotherapy
tumours using an enzyme assay which does not distinguish
between the sub-types.
In cell lines (Cowan et al., 1986), as well as solid tumours
(Keith et al., 1990) investigators have sought a correlation
between GSTi expression and the multi-drug resistance
phenotype (MDR 1 expression) on the assumption of co-
regulation of resistance mechanisms. The drugs used in the
present study comprised either alkylating agents or cis-
platinum, and hence MDR-1 expression would be expected
to be less important than other mechanisms such as
glutathione transferase mediated detoxification, which has
been well-characterised as an important mechanism of
alkylating agent resistance (Teicher & Frei, 1991). Increased
GST expression has been found in rat and Chinese ovary
cells resistant to chlorambucil, rat glioma cells resistant to
nitrogen mustard and human cells resistant to cisplatinum
(Wang & Tew, 1985; Lewis et al., 1988; Evans et al., 1987;
Teicher et al., 1987). The role of the individual sub-types of
GST in relation to resistance to anticancer agents has still
not been resolved although GSTx has been the most fre-
quently studied (Tew et al., 1990). It has been shown that
GSTy class have the highest activity in the detoxication of
nitrosoureas in the rat (Smith et al., 1989). In the yeast S.
cerevisiae transfection of a and x GST has been shown to
give rise to increased resistance to doxorubicin and chloram-
bucil (Black et al., 1990) and transfection of GSTI into NIH
3T3 cells provided a degree of protection against doxo-
rubicin, but not against alkylating agents or cisplatinum
(Nakagawa et al., 1990). However, in human breast cancer
cells, Moscow et al. (1989) found that transfection of GSTi
produced no increased resistance to chlorambucil, melphalan,
or doxorubicin.
The GSTir sub-type has been shown to be 2-5 fold
overexpressed in neoplastic compared to normal tissues in
human breast and ovarian tissues (Buser et al., 1991). This
enzyme has been shown to be capable of catalysing conjuga-
tion of glutathione with electrophiles including cytotoxic
drugs (Dulik et al., 1986). It is the most ubiquitous of the
GST sub-types, and is known to be inducible in response to a
number of extracellular stimuli, and show increased expres-
sion during malignant transformation (Sato, 1988). It is
therefore possible that the level of GSTi expression con-
tributes to the intrinsic resistance of ovarian tumours, by a
process that is related to the mechanism of malignant trans-
formation. The glutathione transferases are subject to trans-
criptional regulation, and are known to be important in
detoxification ofchemical carcinogens (Mannervik, 1985) and
hence their overexpression may also be an important facet of
acquired cytotoxic drug resistance. This study has shown
there is a relationship between qualitative measurement of
GSTi and category of response to anticancer drugs in
ovarian cancer tissues.
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